ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

Long-term Follow-up Shows ADH and ALH Tissue Abnormalities Can Carry Similar Risk

January 31, 2014

CTEP Analyses Proposals For Changes In Cooperative Groups

April 25, 1986

Accrediting Agency Places Dana-Farber On Probation

April 21, 1995

Abstracts Of Papers Presented By Breast Cancer Task Force

August 27, 1976

Gleevec To Prevent Recurrence Of Gastrointestinal Cancer

December 26, 2008

Dendreon Claims “Clear Hit” On Provenge, But Skeptics Await Data Presentation

April 17, 2009